BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22267707)

  • 1. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
    West NR; Murphy LC; Watson PH
    Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
    Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
    Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
    West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
    Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncostatin M/Oncostatin M Receptor Signal Induces Radiation-Induced Heart Fibrosis by Regulating SMAD4 in Fibroblast.
    Xu P; Yi Y; Xiong L; Luo Y; Xie C; Luo D; Zeng Z; Liu A
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):203-217. PubMed ID: 37610394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis.
    Liu J; Zhong Y; Liu H; Yang H; Lu P; Shi Y; Wang X; Zheng W; Yu X; Xu Y; Yang B
    J Dermatol Sci; 2021 Nov; 104(2):95-103. PubMed ID: 34674925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor negativity in breast cancer: a cause or consequence?
    Gajulapalli VNR; Malisetty VL; Chitta SK; Manavathi B
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27884978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.
    Lee BY; Hogg EKJ; Below CR; Kononov A; Blanco-Gomez A; Heider F; Xu J; Hutton C; Zhang X; Scheidt T; Beattie K; Lamarca A; McNamara M; Valle JW; Jørgensen C
    Nat Commun; 2021 Dec; 12(1):7336. PubMed ID: 34921158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
    Dunbier AK; Anderson H; Ghazoui Z; Lopez-Knowles E; Pancholi S; Ribas R; Drury S; Sidhu K; Leary A; Martin LA; Dowsett M
    PLoS Genet; 2011 Apr; 7(4):e1001382. PubMed ID: 21552322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis.
    Marden G; Wan Q; Wilks J; Nevin K; Feeney M; Wisniacki N; Trojanowski M; Bujor A; Stawski L; Trojanowska M
    Arthritis Res Ther; 2020 Jul; 22(1):179. PubMed ID: 32736577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
    Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
    Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence to support bimodality of oestrogen receptor expression in breast cancer.
    Muftah AA; Aleskandarany M; Sonbul SN; Nolan CC; Diez Rodriguez M; Caldas C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Feb; 70(3):456-465. PubMed ID: 27648723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.
    Caffarel MM; Coleman N
    J Pathol; 2014 Mar; 232(4):386-90. PubMed ID: 24659184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M signaling drives cancer-associated skeletal muscle wasting.
    Domaniku-Waraich A; Agca S; Toledo B; Sucuoglu M; Özen SD; Bilgic SN; Arabaci DH; Kashgari AE; Kir S
    Cell Rep Med; 2024 Apr; 5(4):101498. PubMed ID: 38569555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
    Wolf CL; Pruett C; Lighter D; Jorcyk CL
    Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.
    Hara T; Chanoch-Myers R; Mathewson ND; Myskiw C; Atta L; Bussema L; Eichhorn SW; Greenwald AC; Kinker GS; Rodman C; Gonzalez Castro LN; Wakimoto H; Rozenblatt-Rosen O; Zhuang X; Fan J; Hunter T; Verma IM; Wucherpfennig KW; Regev A; Suvà ML; Tirosh I
    Cancer Cell; 2021 Jun; 39(6):779-792.e11. PubMed ID: 34087162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.
    Abdel-Fatah TM; Russell R; Agarwal D; Moseley P; Abayomi MA; Perry C; Albarakati N; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
    Mol Oncol; 2014 May; 8(3):520-32. PubMed ID: 24462520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL-6/JAK-induced cancer cell plasticity.
    Peyvandi S; Bulliard M; Yilmaz A; Kauzlaric A; Marcone R; Haerri L; Coquoz O; Huang YT; Duffey N; Gafner L; Lorusso G; Fournier N; Lan Q; Rüegg C
    J Clin Invest; 2024 Jan; 134(6):. PubMed ID: 38236642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin M's Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation.
    Ishikawa C; Takeno S; Okamoto Y; Kawasumi T; Kakimoto T; Takemoto K; Nishida M; Ishino T; Hamamoto T; Ueda T; Tanaka A
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of an
    Schwartz LS; Saxl RL; Stearns T; Trowbridge JJ
    bioRxiv; 2023 Nov; ():. PubMed ID: 37961653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic resistance to anti-oestrogen therapy in breast cancer.
    Will M; Liang J; Metcalfe C; Chandarlapaty S
    Nat Rev Cancer; 2023 Oct; 23(10):673-685. PubMed ID: 37500767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.